GoPath Diagnostics

10/29/2025

From the Freedom Trail to the future of molecular testing—Boston, we’re coming your way!

Join us at booth 1110 during the AMP 2025 Annual Meeting & Expo to explore our OncoTarget Series and see how precision genomic profiling is transforming advanced cancer care.

The countdown to AMP 2025 is on—we can’t wait to connect with you in Boston!

10/27/2025

Danielle’s story is a reminder of how genetic testing can change — and even save — lives.

After losing her grandfather and aunt to breast cancer, and with her twin sister’s diagnosis at age 32, Danielle pursued genetic testing and learned she carried a BRCA mutation. The results revealed early-stage breast cancer, allowing her to begin treatment before the disease could progress.

She now encourages others with a family history of breast cancer to talk to their doctors about genetic testing—it may be the most important decision they make.

📖 Read the full story from the National Breast Cancer Foundation: https://www.nationalbreastcancer.org/blog/the-power-of-genetic-testing-danielles-familys-story/

Genetic testing revealed a BRCA gene mutation for Danielle and her twin sister. Danielle's decision to be proactive may have saved her life.

10/24/2025

Breast cancer remains a leading health concern for women in the U.S. One in eight women will face a diagnosis in their lifetime, and rates continue to rise in certain age groups. While earlier detection and improved treatments have increased survival, thousands still lose their lives each year. These figures highlight the ongoing need for awareness, regular screening, and timely care. This Breast Cancer Awareness Month, we’re sharing the numbers that matter.

10/23/2025

👨‍👩‍👧 When should discussions about hereditary risk ideally begin?

1. After a cancer diagnosis
2. When there’s a strong family history
3. During routine preventive care
4. Not sure

💬 Tell us when you think genetic risk conversations should happen.

10/22/2025

Redefining what’s possible in urologic genomics.
Join us at the 2025 LUGPA Annual Meeting to see how our latest genomic and genetic testing solutions are helping urologists deliver more precise, data-driven care. Our solutions include:

✅ PROSTATENOW – Genetic testing for accurate prostate cancer risk assessment.
✅ OncoTarget 500 – Comprehensive genomic profiling to guide individualized treatment.
✅ Integrated Genomic Tools – Learn how to seamlessly implement genomic insights into everyday practice.

10/17/2025

🧬 For patients with a strong family history of breast or ovarian cancer, which test is most useful for risk assessment?

(View the comment section for the answer and explanation)

A. Tumor-only sequencing
B. Germline genetic testing
C. Imaging studies
D. Serum tumor markers

10/14/2025

From lobsters to labs, Boston, we’re ready to showcase what’s next in molecular testing!

We're excited to be attending the AMP 2025 Annual Meeting & Expo in Boston, where we will showcase our OncoTarget Series, designed to provide precision genomic profiling for advanced cancers.

Visit us at booth 1110 to learn more about our OncoTarget Series, molecular testing, and biopharma programs.

10/13/2025

💗 When 36-year-old Sarah first felt a lump, she never imagined it would lead to both a breast cancer diagnosis and the discovery of a BRCA1 gene mutation. Genetic testing revealed the mutation came through her father’s side, a hidden risk passed silently through generations. Though the news was difficult, Sarah found strength in knowing her diagnosis could help protect her daughters and family through early testing and preventive choices. Her story reminds us that awareness and knowledge can save lives.

Learn more about Sarah’s journey from the CDC: https://www.cdc.gov/breast-ovarian-cancer-hereditary/stories/index.html

Personal stories from people with hereditary breast cancer.

10/08/2025

October reminds us that breast cancer risk isn’t only environmental or sporadic; some cases are hereditary. Identifying patients with inherited mutations is essential for guiding personalized breast cancer risk management. Genetic testing helps clinicians pinpoint those who may benefit from earlier or more frequent screening.

10/07/2025

We’re excited to be back in Chicago for the 2025 LUGPA Annual Meeting! Visit us at booth 410 to explore our ProstateNow Germline Panel, designed to support precision and efficiency in urology practices. Don’t miss the opportunity to discover how our solutions help enhance diagnostic confidence and improve patient outcomes.

10/03/2025

Breast cancer is not limited to women. Men who inherit BRCA1 or BRCA2 mutations also have an increased risk for breast, prostate, and pancreatic cancers. Genetic testing can provide valuable insights for both men and women, supporting the prevention and early detection of diseases.

10/01/2025

👉 October is Breast Cancer Awareness Month.

A time to raise awareness and share information about prevention, early detection, and support for those affected. Regular screenings and understanding risk factors can significantly impact outcomes. Throughout this month, we will be highlighting resources, patient stories, and important updates in breast cancer care.